Xilong Scientific Co., Ltd.

SZSE:002584 Stock Report

Market Cap: CN¥5.7b

Xilong Scientific Past Earnings Performance

Past criteria checks 3/6

Xilong Scientific's earnings have been declining at an average annual rate of -12.7%, while the Chemicals industry saw earnings declining at 0.5% annually. Revenues have been growing at an average rate of 9.3% per year. Xilong Scientific's return on equity is 2.8%, and it has net margins of 0.8%.

Key information

-12.72%

Earnings growth rate

-13.23%

EPS growth rate

Chemicals Industry Growth12.10%
Revenue growth rate9.32%
Return on equity2.79%
Net Margin0.83%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Investors Will Want Xilong Scientific's (SZSE:002584) Growth In ROCE To Persist

Apr 01
Investors Will Want Xilong Scientific's (SZSE:002584) Growth In ROCE To Persist

Some Shareholders Feeling Restless Over Xilong Scientific Co., Ltd.'s (SZSE:002584) P/E Ratio

Nov 27
Some Shareholders Feeling Restless Over Xilong Scientific Co., Ltd.'s (SZSE:002584) P/E Ratio

Here's What To Make Of Xilong Scientific's (SZSE:002584) Decelerating Rates Of Return

Sep 30
Here's What To Make Of Xilong Scientific's (SZSE:002584) Decelerating Rates Of Return

Xilong Scientific (SZSE:002584) Will Want To Turn Around Its Return Trends

Jun 07
Xilong Scientific (SZSE:002584) Will Want To Turn Around Its Return Trends

Xilong Scientific Co., Ltd. (SZSE:002584) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 22
Xilong Scientific Co., Ltd. (SZSE:002584) Not Doing Enough For Some Investors As Its Shares Slump 26%

Xilong Scientific Co., Ltd. (SZSE:002584) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Mar 08
Xilong Scientific Co., Ltd. (SZSE:002584) Surges 35% Yet Its Low P/S Is No Reason For Excitement

Revenue & Expenses Breakdown

How Xilong Scientific makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:002584 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 257,60563262102
31 Dec 247,81662255110
30 Sep 247,60968256107
30 Jun 247,62364250104
31 Mar 247,08930249110
31 Dec 237,0923324396
30 Sep 237,7173021284
30 Jun 237,2163121670
31 Mar 236,7502021387
01 Jan 236,1838922490
30 Sep 224,778119242109
30 Jun 224,785126242133
31 Mar 225,169252237117
01 Jan 225,380187261119
30 Sep 216,599170191127
30 Jun 216,197163217116
31 Mar 216,51578284105
31 Dec 206,24357265103
30 Sep 205,5095933987
30 Jun 204,9934934782
31 Mar 203,7135130385
31 Dec 193,3383930388
30 Sep 193,0931734288
30 Jun 193,2523931889
31 Mar 193,6104433383
31 Dec 183,3557133982
30 Sep 183,51110330874
30 Jun 183,44410127994
31 Mar 183,3519328277
31 Dec 173,3059028259
30 Sep 173,5727730338
30 Jun 173,422773390
31 Mar 173,166873270
31 Dec 162,928973160
30 Sep 162,6411002940
30 Jun 162,531982880
31 Mar 162,495942790
31 Dec 152,514912750
30 Sep 152,224922730
30 Jun 152,214842720
31 Mar 152,202762580
31 Dec 142,198782540
30 Sep 142,236692300
30 Jun 142,261612160

Quality Earnings: 002584 has a large one-off loss of CN¥38.9M impacting its last 12 months of financial results to 31st March, 2025.

Growing Profit Margin: 002584's current net profit margins (0.8%) are higher than last year (0.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002584's earnings have declined by 12.7% per year over the past 5 years.

Accelerating Growth: 002584's earnings growth over the past year (108.7%) exceeds its 5-year average (-12.7% per year).

Earnings vs Industry: 002584 earnings growth over the past year (108.7%) exceeded the Chemicals industry 4%.


Return on Equity

High ROE: 002584's Return on Equity (2.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/17 23:52
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Xilong Scientific Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shanshan LiChina Merchants Securities Co. Ltd.
Zheng ZhouFounder Securities Co., Ltd.
Ye Hui YangHuatai Research